Welcome to Stellenbosch University

​Division of Radiobiology

Peer-reviewed publications

Peer-reviewed publications since 2012

  1. Milambo JPM, Nyasulu PS, Akudugu JM, Ndirangu J. Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study. BMC Res Notes 16:37, 2023. DOI: 10.1186/s13104-023-06301-6
  2. Mallum A, Mkhize T, Akudugu JM, Ngwa W, Vorster M. The role of positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning: a literature review. Diagnostics 13(1):53, 2023. DOI:10.3390/ diagnostics13010053
  3. Milambo JPM, Ndirangu J, Nyasulu PS, Akudugu JM. Feasibility of point of care testing for prevention and management of breast cancer therapy associated comorbidities in 6 African countries. BMC Res Notes 15(1):1-5, 2022. DOI:10.1186/s13104-022-06204-y
  4. Chinhengo A, Serafin A, Akudugu JM. Radiosensitization by low-frequency radiofrequency fields is dependent on the magnitude of the modulating frequency. Plasma Med 12(2):27-36, 2022. DOI:10.1615/PlasmaMed.2022044536
  5. Manunu B, Serafin AM, Akudugu JM. BAG1, MGMT, FOXO1, and DNAJA1 as potential drug targets for radiosensitizing cancer cell lines. Int J Radiat Biol 99(2):292-307, 2022. DOI: 10.1080/09553002.2022.2074164
  6. Serafin A, Chinhengo A, Akudugu JM. Predictive value of malignancy index in tumour staging in prostate cancer. Eur Med J, 2022. DOI:10.33590/emjurol/21-00116.
  7. Hamid M, Serafin A, Akudugu J. Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells. Eur J Pharmacol 912:174612, 2021; DOI: 10.1016/j.ejphar.2021.174612
  8. Pupwe G, Ngalamika O, Akudugu J. Chemotherapy for elderly colorectal cancer patients at a tertiary hospital in South Africa. Pan Afri Med J 37:100, 2020. DOI: 10.11604/pamj.2020.37.100.18515
  9. Serafin A, Chinhengo A, Fernandez P, Akudugu J. The malignancy index is a robust predictor of prostate cancer. Discov Med 29(158):181-189, 2020.
  10. Chinhengo A, Serafin A, Akudugu J. Radiosensitization by radiofrequency fields is correlated with micronucleus yield and proliferative index. Plasma Med 10(1):27-43, 2020. DOI:10.1615/PlasmaMed.2020032821
  11. ​Chinhengo A, Serafin A, Akudugu J. Radiofrequency field–induced radiosensitization is related to reductions in metabolic activity. Plasma Med 9(2):177-190, 2019. DOI:10.1615/PlasmaMed.2020032850
  12. Chinhengo A, Serafin A, Akudugu J. Radiofrequency field–induced radiosensitization is not correlated with induction of reactive oxygen species. Plasma Med 9(2):167-176, 2019. DOI:10.1615/PlasmaMed.2020033041
  13. Chinhengo A, Serafin A, Akudugu J. Radiofrequency fields preferentially enhance in vitro cellular radiosensitivity to large fractional doses in a p53-dependent manner. Plasma Med 9(2):147-166, 2019. DOI:10.1615/PlasmaMed.2020032818
  14. Maleka S, Serafin A, Akudugu J. PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells. Int J Radiat Res 17(1):37-45, 2019. DOI: 10.18869/acadpub.ijrr.17.1.37
  15. Chinhengo A, Serafin A, Akudugu J. Comparison of cellular sensitivity to a split radiation dose and a combination of a single radiation dose and electromagnetic field exposure. Plasma Med 9(1):15-22, 2019. DOI:10.1615/PlasmaMed.2018027349
  16. Ali NS, Akudugu JM, Howell RW. A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-EpCAM (9C4). World J Nucl Med 18:18-24, 2019; DOI:10.4103/wjnm.WJNM_9_18
  17. Serafin A, Chinhengo A, Fernandez P, Akudugu J. The malignancy index in plasma samples as a prostate cancer biomarker. Discov Med 25(139):235-242, 2018.
  18. Chinhengo A, Serafin A, Hamman B, Akudugu J. Electromagnetic fields induce frequency-dependent radioprotection and radiosensitization in in vitro cell cultures. Plasma Med 8(2):163-175, 2018; DOI:10.1615/PlasmaMed.2018020991 
  19. Hamman B, Chinhengo A, Serafin A, Sewram V, Akudugu J. Radiomodifying Effects of Centella asiatica and Withania somnifera. J Herbs Spices Med Plants 24(3):221-228, 2018;DOI:10.1080/10496475.2018.1443540
  20. Serafin A, Chinhengo A, Fernandez P, Akudugu J. A multi-parameter approach for predicting prostate cancer. Cogent Med 4:1329257, 2017; DOI:10.1080/2331205X.2017.1329257
  21. Hamunyela RH, Serafin AM, Akudugu JM. Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells. Toxicol In Vitro 38:117-123, 2017; DOI:10.1016/j.tiv.2016.10.002
  22. Achel DG, Achoribo  E, Agbenyegah S, Adaboro RM, Donkor S, Adu Bobi NNA-K, Agyekum AA, Akoamoa F, Tagoe SN, Kyei KA, Yarnney J, Serafin A, Akudugu JM. Towards establishing capacity for biological dosimetry at Ghana Atomic Energy Commission. Genome Integrity 7:3, 2016; DOI:10.4103/2041-9414.197173
  23. Hamunyela R, Serafin A, Akudugu J. Combined inhibition of PI3K, mTOR and Bcl-2 significantly radiosensitises progesterone and oestrogen receptor negative breast cancer cells. J Cancer Biol Therap 1:101-108, 2016; DOI:10.18314/gjct.v2i1.138
  24. Achel DG, Serafin AM, Akudugu JM. Flow cytometry-assisted quantification of γH2AX expression has potential as a rapid high-throughput biodosimetry tool. Radiat Environ Biophys 55:349-357, 2016; DOI:10.1007/s00411-016-0654-5
  25. Kemp FW, Portugal F, Akudugu JM, Neti PVSV, Ferraris RP, Howell RW. Vitamins A, C, and E may reduce intestinal Po-210 levels after ingestion. Health Phys 111:52-57, 2016; DOI:10.1097/HP.0000000000000512
  26. Serafin A, Böhm L, Fernandez P, Achel D, Akudugu J. The potential of PAI-1 expression in needle biopsies as a predictive marker for prostate cancer. Cogent Med 3:1183275, 2016; DOI:10.1080/2331205X.2016.1183275
  27. Hamid M, Hamunyela R, Serafin A, Akudugu J. Inhibition of PI3K and mTOR sensitises oestrogen receptor positive human breast cancer cells to a large fraction of radiation dose. J Cancer Biol Therap 1:93-100, 2016; DOI:10.18314/gjct.v1i2.74
  28. Achel DG, Serafin AM, Achoribo EA, Agbenyegah S, Akudugu JM. In vitro cytotoxicity and radiomodifying effects of aqueous extracts of Moringa oleifera (Lam). Elixir Biosciences 90:37431-37435, 2016;
  29. Vawda Z, Pitcher R, Akudugu J, Groenewald W. Diagnostic reference levels for paediatric computed tomography. S Afr J Rad 2015;19(2); Art. #846, DOI:10.4102/sajr.v19i2.846 ​
  30. Akudugu J, Serafin A. Estimation of transition doses for human glioblastoma, neuroblastoma and prostate cell lines using the linear-quadratic formalism. Int J Cancer Ther Oncol 2015; 3(3):3311; DOI:10.14319/ijcto.33.11 
  31. Hamunyela R, Serafin A, Hamid M, Maleka S, Achel D, Akudugu J. A cocktail of specific inhibitors of HER-2, PI3K, and mTOR radiosensitises human breast cancer cells. J Cancer Biol Therap 1:45-56, 2015; DOI:10.18314/gjct.v1i1.33
  32. Maleka S, Serafin A, Hamunyela R, Hamid M, Achel D, Akudugu J. NVP-BEZ235 enhances radiosensitivity of human prostate cancer cells but acts as a radioprotector to normal prostate cells. J Cancer Biol Therap 1:38-45, 2015; DOI:10.18314/gjct.v1i1.32
  33. Akudugu J, Serafin A. The role of Bak-mediated dissipation of mitochondrial membrane potential in radiosensitivity of Bax-negative human prostate cancer cells. J Med Sci Res 3:27-32, 2015; DOI:10.17727/JMSR.2015/3-004
  34. Akudugu J, Serafin A, Böhm L. Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. J Cancer Res Clin Oncol 141:627–631, 2015; DOI:10.1007/s00432-014-1848-3
  35. Serafin AM, Akudugu JM, Böhm L. Influence of freeze-drying on the recovery of the tumour invasion markers uPA and PAI-1 from prostate cancer resections. Annals Clin Biochem 52(3):387-394, 2015; DOI:10.1177/0004563214559546
  36. Pasternack JB, Domogauer JD, Khullar A, Akudugu JM, Howell RW. The advantage of antibody cocktails fortargeted alpha therapy depends on specific activity. J Nucl Med 55:2012–1219, 2014; DOI:10.2967/jnumed.114.141580
  37. Böhm L, Serafin AM, Akudugu JM, Fernandez P, van der Merwe A, Aziz NA. uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer. J Cancer Res Clin Oncol 139(7):1221-1228, 2013; DOI:10.1007/s00432-013-1428-y
  38. Akudugu JM, Serafin AM, Böhm LJF. In vitro radiosensitization by pentoxifylline does not depend on p53 status. Int J Radiat Biol 89(6):462-470, 2013; DOI:10.3109/09553002.2013.766771
  39. Akudugu JM, Howell RW. A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: Validation with daunomycin, doxorubicin, and the alpha particle emitter 210Po. Nucl Med Biol 39(7):954-961, 2012; DOI:10.1016/j.nucmedbio.2012.01.011
  40. Akudugu JM, Azzam EI, Howell RW. Induction of bystander effects in human breast cancer cell cultures by DNA-incorporated Iodine-125 depends on phenotype. Int J Radiat Biol 88(12):1028-1038, 2012; DOI:10.3109/09553002.2012.683511
  41. Akudugu JM, Howell RW. Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs. Int J Radiat Biol 88(3):286-293, 2012; DOI:10.3109/09553002.2012.638357